Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 6/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | PLAT | P00750 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | ADH5 | P11766 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248182 | 0.91 | CHEK2 (0.44) | MAP4K4CHEK2MAPKAPK2PTPN11PLAU | |
| SCHEMBL242923 | 0.85 | PTPN11 (0.46) | MAP4K4CHEK2MAPKAPK2PTPN11PLAU | |
| SCHEMBL243838 | 0.84 | MAPKAPK2 (0.45) | MAP4K4CHEK2MAPKAPK2PTPN11PLAU | |
| SCHEMBL245768 | 0.81 | MAPKAPK2 (0.45) | MAP4K4CHEK2MAPKAPK2PTPN11PLAU | |
| SCHEMBL249222 | 0.79 | SMN1; SMN2 (0.41) | MAP4K4CHEK2MAPKAPK2PTPN11PLAU | |
| SCHEMBL245309 | 0.79 | SMN1; SMN2 (0.41) | CHEK2MAPKAPK2PLAUPLATSMN1; SMN2 | |
| SCHEMBL244774 | 0.78 | SMN1; SMN2 (0.41) | MAP4K4CHEK2MAPKAPK2PTPN11PLAU | |
| SCHEMBL242932 | 0.78 | SMN1; SMN2 (0.41) | MAP4K4CHEK2MAPKAPK2PTPN11PLAU | |
| SCHEMBL242470 | 0.77 | PLAU (0.40) | MAP4K4CHEK2MAPKAPK2PLAUPLAT | |
| SCHEMBL244225 | 0.76 | CA9 (0.46) | MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029402-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase | NIVALIS THERAPEUTICS, INC. (US) | 2015-05-12 | — | — | US | claimed |
| US-20140113938-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | NIVALIS THERAPEUTICS, INC. | 2014-04-24 | — | — | US | claimed |
| US-8642628-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase | N30 PHARMACEUTICALS, INC. (US) | 2014-02-04 | — | — | US | claimed |
| EP-2315590-B1 | PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS LLC (US) | 2012-09-26 | — | — | EP | claimed |
| JP-2012500218-A | — | — | 2012-01-05 | — | — | JP | claimed |
| US-20110136875-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, LLC (US) | 2011-06-09 | — | — | US | claimed |
| EP-2315590-A1 | PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 Pharmaceuticals, LLC (US) | 2011-05-04 | — | — | EP | claimed |
| WO-2010019909-A1 | PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS, LLC (US) | 2010-02-18 | — | — | WO | claimed |
| US-9029402-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase | NIVALIS THERAPEUTICS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029402-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase | NIVALIS THERAPEUTICS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029402-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase | NIVALIS THERAPEUTICS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140113938-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | NIVALIS THERAPEUTICS, INC. | 2014-04-24 | — | — | US | disclosed |
| US-20140113938-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | NIVALIS THERAPEUTICS, INC. | 2014-04-24 | — | — | US | disclosed |
| US-20140113938-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | NIVALIS THERAPEUTICS, INC. | 2014-04-24 | — | — | US | disclosed |
| US-20110136875-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, LLC (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136875-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, LLC (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136875-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, LLC (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2315590-A1 | PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 Pharmaceuticals, LLC (US) | 2011-05-04 | — | — | EP | disclosed |
| WO-2010019909-A1 | PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS, LLC (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019909-A1 | PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS, LLC (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136875-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | GSR, GRHPR, POR | MAP4K4 4290/4885CHEK2 3530/4885EGLN1 1830/4885 |
| US-20140113938-A1 | Pyrrole Inhibitors of S-Nitrosoglutathione Reductase | GSR, GRHPR, POR | MAP4K4 4290/4885CHEK2 3530/4885EGLN1 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.